We studied registry data of 12,944 adult kidney retransplant recipients categorized by induction regimen received into\nantithymocyte globulin (ATG) (N = 9120), alemtuzumab (N = 1687), and basiliximab (N = 2137) cohorts.We analyzed risk factors\nfor 1-year acute rejection (AR) and 5-year death-censored graft loss (DCGL) and patient death. Compared with the reference,\nbasiliximab: (1) one-year AR risk was lower with ATG in retransplant recipients of expanded criteria deceased-donor kidneys (HR\n= 0.56, 95% CI = 0.35ââ?¬â??0.91 and HR = 0.54, 95% CI = 0.27ââ?¬â??1.08, resp.), while AR risk was lower with alemtuzumab in retransplant\nrecipients with >3 HLA mismatches before transplant (HR = 0.63, 95% CI = 0.44ââ?¬â??0.93 and HR = 0.81, 95% CI = 0.63ââ?¬â??1.06, resp.);\n(2) five-year DCGL risk was lower with alemtuzumab, not ATG, in retransplant recipients of African American race (HR = 0.54,\n95% CI = 0.34ââ?¬â??0.86 and HR = 0.73, 95% CI = 0.51ââ?¬â??1.04, resp.) or with pretransplant glomerulonephritis (HR = 0.65, 95% CI =\n0.43ââ?¬â??0.98 and HR = 0.82, 95% CI = 0.60ââ?¬â??1.12, resp.). Therefore, specific risk factor-induction regimen combinations may predict\noutcomes and this information may help in individualizing induction in retransplant recipients.
Loading....